內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Visfatin (VF) ,etc. by FLIA (Flow Luminescence Immunoassay)
Nampt; NAmPRTase; PBEF; PBEF1; Pre-B-Cell Colony Enhancing Factor; Nicotinamide Phosphoribosyltransferase
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)LMA638Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.1-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.033 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2427 ¥ 2521 ¥ 2661 ¥ 2847 ¥ 3034 ¥ 3314 ¥ 3734 ¥ 4668 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 85-98 | 90 |
| EDTA plasma(n=5) | 79-91 | 84 |
| heparin plasma(n=5) | 84-92 | 89 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 99-105% | 94-101% | 79-101% | 80-95% |
| EDTA plasma(n=5) | 95-103% | 94-101% | 79-101% | 87-94% |
| heparin plasma(n=5) | 95-105% | 90-104% | 89-98% | 88-95% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA638Mu02 | 內(nèi)脂素(VF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA638Mu01 | 內(nèi)脂素(VF)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA638Mu01 | 內(nèi)脂素(VF)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA638Mu02 | 內(nèi)脂素(VF)多克隆抗體 | WB; IHC; ICC; IP. |
| SEA638Mu | 內(nèi)脂素(VF)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEA638Mu | 內(nèi)脂素(VF)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA638Mu | 內(nèi)脂素(VF)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Brazilian Journal of Biomoricity | EFFECT OF 8 WEEKS ENDURANCE TRAINING ON PLASMA VISFATIN IN MIDDLE-AGED MEN [Brjb: source] |
| Diabetes Research and Clinical Practice | The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance [ScienceDirect: S0168822711002956] |
| J Physiol Pharmacol. | Early-effect of bariatric surgery (Scopinaro method) on intestinal hormones and adipokines in insulin resistant Wistar rat. [Pubmed: 24304571] |
| Endocr J. | CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes [Pubmed:25168658] |
| Exp Ther Med. | Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome [Pubmed:Pmc3991522] |
| Eur J Cancer Prev. | Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization. [Pubmed:25055182] |
| Genome | Visfatin ?948G/T?and resistin ?420C/Gpolymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases [Nrcresearchpress:Source] |
| PLOS ONE | Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug [PubMed: 26262991] |
| Alcoholism and Drug Addiction | Changes in concentration of visfatin during four weeks of inpatient treatment of alcohol dependent males [Science: Article] |
| Cytokine | Variation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapies [PubMed: 26539806] |
| Genome | Genetic Variations in Visfatin and Resistin Genes in Egyptian Type 2 Diabetic Patients With and Without Complications [PubMed: 25120107] |
| Acta Histochemica | Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines [science:S0065128116301234] |
| Endocrine, Metabolic & Immune Disorders-Drug Targets | Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy. [pubmed:28699485] |
| Endocrine?Connections | Post-chemotherapy serum anti-müllerian hormone level predicts ovarian function recovery [Pubmed:30012648] |
| Bioscience Reports | Effect of maternal hypothyroidism during pregnancy on insulin resistance, lipid accumulation and mitochondrial dysfunction in skeletal muscle of fetal rats [Pubmed:29784871] |
| Contraception | Hyperinsulinemic-euglycemic clamp over the first year of use of depot-medroxyprogesterone acetate as a contraceptive [Pubmed:29665358] |
| Cranio?-?Journal?of?Craniomandibular?Practice | Analysis of synovial fluid visfatin level in temporomandibular joint disorders [Pubmed:29385907] |
| Nutrire | Resistin and visfatin concentrations are related to central obesity and inflammation in Brazilian children [10.1186:s41110-018-0060-7] |
| DNA?and?Cell?Biology | Transcriptional Regulation of?NAMPT?Gene by Glycogen Synthase Kinase 3β in Goat Adipocytes [Pubmed: 30615481] |
| Jundishapur?Journal of?Chronic?Disease?Care | The Effect of 8 Weeks Aquatic Exercise Program on Plasma Visfatin Level and Some Blood Factors in Obese Men [] |
| Biomarkers in Heart Failure and Associated Diseases | Adipokines as Biomarkers in Health and Disease [] |
| Journal of Translational Medicine | Plasma concentration and expression of adipokines in epicardial and subcutaneous adipose tissue are associated with impaired left ventricular filling pattern [Pubmed: 31533725] |
| clinical neurology and neurosurgery | Relationsh?p of spontaneous subarachnoid haemorrhage and cerebral aneurysm to serum Visfatin and Nesfatin-1 levels [Pubmed: 32311618] |
| The Horizon of Medical Sciences | Effects of 10-Week Concurrent Training on Insulin Resistance and the Serum Levels of Vaspin and Visfatin in Overweight Females [] |
| EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY | Different Ratios of Corn and Coconut Oil Blends in High?\Fat Diets Influence Fat Deposition without Altering Metabolic Biomarkers in Male Rats [] |
